Complete Acid Reducer Tablet, Chewable
NDC Package 51316-588-63
Package Information
Complete Acid Reducer (famotidine, calcium carbonate, magnesium hydroxide) tablets is •adults and children 12 years and over:•do not swallow tablet whole: chew completely•to relieve symptoms, chew 1 tablet before swallowing•do not use more than 2 chewable tablets in 24 hours•children under 12 years: ask a doctor. This formulation utilizes a tablet, chewable delivery system. Marketed by Cvs Woonsocket Prescription Center, Incorporated, this product is identified by NDC 51316-588 and is authorized under FDA application ANDA077355.
Identification & Billing
- RxCUI: 283641 - famotidine 10 MG / calcium carbonate 800 MG / magnesium hydroxide 165 MG Chewable Tablet
- RxCUI: 283641 - calcium carbonate 800 MG / famotidine 10 MG / magnesium hydroxide 165 MG Chewable Tablet
- RxCUI: 283641 - calcium carbonate 800 MG / famotidine 10 MG / milk of magnesia 165 MG Chewable Tablet
Clinical Specifications
- Blood Coagulation Factor - [EPC] (Established Pharmacologic Class)
- Calcium - [CS]
- Calculi Dissolution Agent - [EPC] (Established Pharmacologic Class)
- Cations, Divalent - [CS]
- Histamine H2 Receptor Antagonists - [MoA] (Mechanism of Action)
- Histamine-2 Receptor Antagonist - [EPC] (Established Pharmacologic Class)
- Increased Coagulation Factor Activity - [PE] (Physiologic Effect)
- Increased Large Intestinal Motility - [PE] (Physiologic Effect)
- Inhibition Large Intestine Fluid/Electrolyte Absorption - [PE] (Physiologic Effect)
- Inhibition Small Intestine Fluid/Electrolyte Absorption - [PE] (Physiologic Effect)
- Magnesium Ion Exchange Activity - [MoA] (Mechanism of Action)
- Osmotic Activity - [MoA] (Mechanism of Action)
- Osmotic Laxative - [EPC] (Established Pharmacologic Class)
- Phosphate Binder - [EPC] (Established Pharmacologic Class)
- Phosphate Chelating Activity - [MoA] (Mechanism of Action)
- Stimulation Large Intestine Fluid/Electrolyte Secretion - [PE] (Physiologic Effect)
Regulatory & Marketing
Hierarchy Structure
- 51316 - Cvs Woonsocket Prescription Center, Incorporated
- 51316-588 - Complete Acid Reducer
- 51316-588-63 - 25 TABLET, CHEWABLE in 1 BOTTLE
- 51316-588 - Complete Acid Reducer
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 51316-588-63 identifies a specific commercial package of 25 tablet, chewable in 1 bottle of Complete Acid Reducer, a human over the counter drug labeled by Cvs Woonsocket Prescription Center, Incorporated. This tablet, chewable is formulated for oral use and contains calcium carbonate; famotidine; magnesium hydroxide as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Cvs Woonsocket Prescription Center, Incorporated on April 06, 2026. The current certification is valid through December 31, 2027.
How is this Cvs Woonsocket Prescription Center, Incorporated product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 51316058863. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.